基蛋生物(603387) - 2024 Q3 - 季度财报(更正)

Financial Performance - The company's operating revenue for the third quarter was ¥262,156,808.27, a decrease of 11.91% compared to the same period last year[4] - Net profit attributable to shareholders was ¥28,609,951.22, down 52.59% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥18,988,078.64, reflecting a decline of 65.47% compared to the previous year[4] - In the first three quarters of 2024, the company achieved operating revenue of CNY 880 million, a decrease of 12.10% year-on-year[15] - The net profit attributable to shareholders was CNY 175 million, down 23.42% compared to the same period last year[15] - Total operating revenue for the first three quarters of 2024 was ¥879,824,587.76, a decrease of 12.1% compared to ¥1,000,961,989.28 in the same period of 2023[23] - Net profit for the first three quarters of 2024 was ¥181,904,536.85, a decline of 22.2% from ¥233,662,791.59 in the previous year[24] - Total comprehensive income for the period was CNY 189,620,691.30, a decrease from CNY 234,143,463.91 in the previous year[25] Earnings and Shareholder Returns - Basic and diluted earnings per share were both ¥0.06, a decrease of 50.00% compared to the same period last year[4] - Basic and diluted earnings per share decreased to CNY 0.35 from CNY 0.45 year-over-year[25] - The weighted average return on equity decreased to 1.10%, down 1.32 percentage points year-on-year[4] Cash Flow and Liquidity - Cash flow from operating activities for the year-to-date was ¥249,907,045.22, an increase of 70.58%[4] - The cash and cash equivalents as of September 30, 2024, were CNY 536.59 million, up from CNY 484.33 million at the end of 2023[18] - The company's cash and cash equivalents decreased to ¥1,930,829,694.44 from ¥2,151,184,140.66 year-over-year[20] - Net cash flow from operating activities increased to CNY 249,907,045.22, compared to CNY 146,507,664.68 in the same period last year, representing a growth of 70.5%[28] - Cash inflow from operating activities totaled CNY 1,125,151,015.42, down from CNY 1,268,627,997.86, a decline of 11.3%[27] - Cash outflow from operating activities decreased to CNY 875,243,970.20 from CNY 1,122,120,333.18, a reduction of 22.0%[28] - Net cash flow from investing activities was negative at CNY -139,612,486.27, an improvement from CNY -349,098,239.79 in the previous year[28] - Cash flow from financing activities resulted in a net outflow of CNY -53,954,549.19, compared to CNY -38,940,372.59 last year[28] - The ending cash and cash equivalents balance increased to CNY 536,086,628.64 from CNY 407,471,086.12 year-over-year[29] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,839,310,398.65, an increase of 4.40% from the end of the previous year[5] - Total liabilities increased to ¥1,161,681,548.46, compared to ¥1,030,379,608.82 in the previous year[20] - The total owner's equity decreased slightly to ¥2,677,628,850.19 from ¥2,741,246,444.12 year-over-year[21] - The company reported a significant increase in long-term equity investments, rising to ¥122,870,201.52 from ¥50,873,981.61[20] Operational Highlights - The core product, Getein1600, had over 400 units installed in the first three quarters of 2024[15] - The sales revenue from the chemical luminescence line reached CNY 196 million, an increase of 38.43% year-on-year[15] - The overseas revenue from conventional products was CNY 84.99 million, a year-on-year increase of 20.31%[16] - The company installed over 710 units of the small luminescence product MAGICL6000 and MAGICL6000i in various hospitals[15] - The company has installed over 70 units of the Metis6000 fully automated biochemical immunoassay line since its launch[15] Non-Recurring Items - The company recognized government subsidies amounting to ¥6,537,901.80 during the reporting period, contributing positively to the financial results[8] - Non-recurring gains and losses totaled ¥9,621,913.14 for the current period, with a significant portion attributed to government subsidies and other income[9] Changes in Consolidation - The company has decided to no longer consolidate Wuhan Jingchuan Diagnostic Technology Co., Ltd. into its financial statements starting July 1, 2024[16]